Jiangsu Chia Tai Qingjiang Pharmaceutical Co. Ltd. has synthesized peptide epoxyketone compounds acting as proteasome inhibitors. They are reported to be useful for the treatment of systemic lupus erythematosus, ulcerative colitis and rheumatoid arthritis.

Asieris Pharmaceuticals Co. Ltd. has patented new prodrugs of fibroblast growth factor receptor 3 (FGFR3) inhibitors potentially useful for the treatment of cancer.

A University of Texas System patent describes new YAP1 degradation inducing proteolysis targeting chimeras (PROTACs) designed for use in the treatment of cancer.

Breye Therapeutics Aps has reported P2X purinoceptor 7 (P2RX7; P2X7) antagonists potentially useful for the treatment of age-related macular degeneration (AMD), cardiovascular, cognitive, eating disorder, headache, liver diseases, neurodegeneration and neuroinflammation, among others.

Boomray Co. Ltd. has prepared and tested new peptide-drug conjugates comprising a radionuclide-labeled probe linked to a fibroblast activation protein α (FAP)-targeting peptide. They are reported to be useful for the diagnosis and treatment of cancer, inflammation, atherosclerosis, fibrosis and scars.

Gasherbrum Bio Inc. has discovered new glucagon-like peptide 1 receptor (GLP-1R) agonists. They are reported to be useful for the treatment of type 2 diabetes, dyslipidemia, hyperglycemia, hypertension, obesity and more.

Eisai Co. Ltd. has patented immunoconjugates comprising monoclonal antibodies targeting 5’-nucleotidase (CD73) covalently linked to cytotoxic drug. They are reported to be useful for the treatment of cancer.

Synnovation Therapeutics Inc. has discovered heterocyclic TNF-α inhibitors designed for use in the treatment of inflammatory disorders and neurodegeneration.

Sunrise Oncology (Hong Kong) Ltd. has disclosed GTPase KRAS inhibitors in a recent patent. They are described as potentially useful for the treatment of cancer.

An F. Hoffmann-la Roche Ltd. and Hoffmann-la Roche Inc. patent describes prodrugs of serine/threonine-protein salt-inducible kinases (SIK) inhibitors. They are reported to be useful for the treatment of atherosclerosis, type 2 diabetes, giant cell arteritis, glomerulonephritis, inflammatory bowel disease, metabolic dysfunction-associated steatohepatitis (MASH; NASH), primary sclerosing cholangitis and rheumatoid arthritis.